Relapsed or Refractory Acute Myeloid Leukemia (AML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Relapsed
or Refractory Acute Myeloid Leukemia (AML) Market Outlook
Thelansis’s “Relapsed or
Refractory Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Relapsed
or Refractory Acute Myeloid Leukemia (AML) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Relapsed or
Refractory Acute Myeloid Leukemia (AML) Overview
Relapsed
or refractory acute myeloid leukemia (r/r AML) is a clinically aggressive
haematological malignancy defined by disease recurrence following remission or
failure to achieve remission after induction chemotherapy, carrying
substantially poor prognosis with conventional salvage approaches. Resistance
mechanisms encompass clonal evolution, acquisition of additional somatic
mutations, leukaemic stem cell persistence, and bone marrow
microenvironment-mediated chemotherapy evasion. Restaging bone marrow biopsy
with comprehensive cytogenetic and molecular mutation profiling is essential,
as mutational landscape evolution frequently occurs at relapse and directly
informs therapeutic selection. Targeted agents have transformed the r/r AML
landscape; gilteritinib is the definitive approved monotherapy standard for
FLT3-mutant relapsed disease, while IDH1 inhibitors ivosidenib and
olutasidenib, and IDH2 inhibitor enasidenib, address their respective
molecularly defined subgroups with meaningful response rates. Menin inhibitors,
including revumenib and ziftomenib, represent the most significant recent
therapeutic advance, inducing deep molecular remissions in highly refractory
KMT2A-rearranged and NPM1-mutated AML where chemotherapy fails.
Venetoclax-based combinations retain broad relevance across molecular
subgroups. Gemtuzumab ozogamicin addresses CD33-positive relapsed disease.
Intensive salvage chemotherapy bridges eligible patients to allogeneic stem
cell transplantation, the only potentially curative option. Prognosis remains
poor; clinical trial enrolment, goals-of-care discussions, and early palliative
integration are indispensable to compassionate patient-centred management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment